TY - JOUR
T1 - Quantitation and visualization of tumor-specific T cells in the secondary lymphoid organs during and after tumor elimination by PET
AU - Matsui, Ken
AU - Wang, Zheng
AU - McCarthy, Timothy J.
AU - Allen, Paul M.
AU - Reichert, David E.
N1 - Funding Information:
The authors wish to acknowledge the following individuals for technical support of this work; Darren Kreamalmeyer, Donna Thompson, Steve Horvath, Joon Young Kim, Jerrel Rutlin, John Engelbach, Nicole Mercer, and Lynne Jones. They would also like to thank Jerri Smith for her secretarial support. Supported by funds from National Institutes of Health, (P50 CA94056). The production of 64 Cu at Washington University is supported by the NCI (R24 CA86307). MicroPET imaging is supported by an NIH/NCI SAIRP grant (1 R24 CA83060). They would also like to thank the Small Animal Imaging Core of the Alvin J. Siteman Cancer Center at Washington University and Barnes-Jewish Hospital in St. Louis, MO, USA, for additional support of the microPET imaging.
PY - 2004/11
Y1 - 2004/11
N2 - Increased understanding in the area of trafficking behavior of adoptively transferred tumor-specific T cells could help develop better therapeutic protocols. We utilized the DUC18/CMS5 tumor model system in conjunction with a microPET scanner to study the DUC18 T cell distribution pattern in spleens and lymph nodes in live mice. Anti-Thy1.2 antibodies conjugated to 1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′- tetraacetic acid (DOTA) and radiolabeled with 64Cu were administered to three groups of BALB-Thy1.1 mice on days 4, 7, or 14 post-DUC18 T cell transfer. We were able to detect the transferred cells in all the major lymph nodes, spleens, and in tumors. Our findings suggest that tumor-specific T cells do not all preferentially localize to the tumors but they also home to all the major lymphoid organs; additionally the number of DUC18 T cells remains relatively constant during and after tumor elimination within each lymphoid organ.
AB - Increased understanding in the area of trafficking behavior of adoptively transferred tumor-specific T cells could help develop better therapeutic protocols. We utilized the DUC18/CMS5 tumor model system in conjunction with a microPET scanner to study the DUC18 T cell distribution pattern in spleens and lymph nodes in live mice. Anti-Thy1.2 antibodies conjugated to 1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′- tetraacetic acid (DOTA) and radiolabeled with 64Cu were administered to three groups of BALB-Thy1.1 mice on days 4, 7, or 14 post-DUC18 T cell transfer. We were able to detect the transferred cells in all the major lymph nodes, spleens, and in tumors. Our findings suggest that tumor-specific T cells do not all preferentially localize to the tumors but they also home to all the major lymphoid organs; additionally the number of DUC18 T cells remains relatively constant during and after tumor elimination within each lymphoid organ.
KW - CMS5
KW - Cu
KW - DOTA
KW - DUC18
KW - Immunotherapy
KW - PET
UR - http://www.scopus.com/inward/record.url?scp=10644222780&partnerID=8YFLogxK
U2 - 10.1016/j.nucmedbio.2004.06.002
DO - 10.1016/j.nucmedbio.2004.06.002
M3 - Article
C2 - 15607484
AN - SCOPUS:10644222780
SN - 0969-8051
VL - 31
SP - 1021
EP - 1031
JO - Nuclear Medicine and Biology
JF - Nuclear Medicine and Biology
IS - 8
ER -